Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia.

Abstract	We report an interesting case of acute myelogenous leukemia (AML) in a Jehovah's Witness patient. A 61-year-old woman, a Jehovah's Witness, consulted our hospital because of continuous fever and refractory pharyngitis. The white blood cell count was increased with myeloblasts and monoblasts, both of which showed positivity for CD33. The level of WT1 messenger RNA (mRNA) in the bone marrow was 130,000 copies/microg RNA. The patient's diagnosis was AML (M4). Because complete remission (CR) was not obtained with 2 courses of chemotherapy consisting of acrarubicin and cytarabine, we tried gemtuzumab ozogamicin (GO) with informed consent. No major side effects appeared, and CR was obtained after 2 courses of GO, which decreased the WT1 mRNA level to 480 copies/microg RNA. The patient has been in CR for 6 months with ubenimex. This case suggests that GO can be one of the treatment options in similar situations, although it should be used with considerable care.
Authors	Shinya Fujisawa, Kensuke Naito, Toshihiko Matsuoka, Masahide Kobayashi
Journal	International journal of hematology (Int J Hematol) Vol. 85 Issue 5 Pg. 418-20 (Jun 2007) ISSN: 0925-5710 [Print] Japan
PMID	17562618 (Publication Type: Case Reports, Journal Article)
Chemical References	Aminoglycosides Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antimetabolites, Antineoplastic Antineoplastic Agents Organic Chemicals acrarubicin Cytarabine Gemtuzumab
Topics	Aminoglycosides (administration & dosage) Antibodies, Monoclonal (administration & dosage) Antibodies, Monoclonal, Humanized Antimetabolites, Antineoplastic (administration & dosage) Antineoplastic Agents (administration & dosage) Antineoplastic Combined Chemotherapy Protocols (administration & dosage) Cytarabine (administration & dosage) Female Gemtuzumab Humans Jehovah's Witnesses Leukemia, Myeloid, Acute (drug therapy) Leukocyte Count Middle Aged Organic Chemicals (administration & dosage) Remission Induction Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!